CN118785906A - 伊普可泮用于治疗狼疮肾炎的用途 - Google Patents

伊普可泮用于治疗狼疮肾炎的用途 Download PDF

Info

Publication number
CN118785906A
CN118785906A CN202380023870.8A CN202380023870A CN118785906A CN 118785906 A CN118785906 A CN 118785906A CN 202380023870 A CN202380023870 A CN 202380023870A CN 118785906 A CN118785906 A CN 118785906A
Authority
CN
China
Prior art keywords
dose
subject
ipracopan
patient
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380023870.8A
Other languages
English (en)
Chinese (zh)
Inventor
J·林尼克
M·迈耶
N·韦伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN118785906A publication Critical patent/CN118785906A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380023870.8A 2022-03-04 2023-03-03 伊普可泮用于治疗狼疮肾炎的用途 Pending CN118785906A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316623P 2022-03-04 2022-03-04
US63/316,623 2022-03-04
PCT/IB2023/052010 WO2023166487A1 (en) 2022-03-04 2023-03-03 Use of iptacopan for the treatment of lupus nephritis

Publications (1)

Publication Number Publication Date
CN118785906A true CN118785906A (zh) 2024-10-15

Family

ID=85704041

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380023870.8A Pending CN118785906A (zh) 2022-03-04 2023-03-03 伊普可泮用于治疗狼疮肾炎的用途

Country Status (10)

Country Link
US (1) US20250195492A1 (https=)
EP (1) EP4486343A1 (https=)
JP (1) JP2025507830A (https=)
KR (1) KR20240155291A (https=)
CN (1) CN118785906A (https=)
AU (1) AU2023229221A1 (https=)
CA (1) CA3248808A1 (https=)
IL (1) IL314494A (https=)
MX (1) MX2024010644A (https=)
WO (1) WO2023166487A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119656165A (zh) * 2023-09-20 2025-03-21 上海美悦生物科技发展有限公司 杂环化合物在制备预防和/或治疗肾脏疾病的药物中的用途
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183512A1 (en) * 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CN120208923A (zh) 2020-05-18 2025-06-27 诺华股份有限公司 Lnp023的结晶形式

Also Published As

Publication number Publication date
AU2023229221A1 (en) 2024-08-15
EP4486343A1 (en) 2025-01-08
IL314494A (en) 2024-09-01
JP2025507830A (ja) 2025-03-21
WO2023166487A1 (en) 2023-09-07
CA3248808A1 (en) 2023-09-07
US20250195492A1 (en) 2025-06-19
KR20240155291A (ko) 2024-10-28
MX2024010644A (es) 2024-09-06

Similar Documents

Publication Publication Date Title
US20200368247A1 (en) Cenicriviroc for the treatment of fibrosis
US20200262897A1 (en) Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
US20200360347A1 (en) Cenicriviroc for the treatment of fibrosis
JP2017526713A (ja) 線維症を処置するためのセニクリビロック併用療法
CN118785906A (zh) 伊普可泮用于治疗狼疮肾炎的用途
EP3185881B1 (en) Methods, agents and compositions for treatment of inflammatory conditions
CN105228453A (zh) 用于治疗与炎症相关的疾病的去乙基羟氯喹
JP2025148449A (ja) クローン病を治療する方法に使用するためのミリキズマブ
KR20240004947A (ko) 비정형 용혈성 요독 증후군 치료용 입타코판
Baldini et al. From clinical trials to the bedside: how can we treat patients with rheumatoid arthritis and concurrent morbidities who are generally excluded from randomised controlled clinical trials
KR20220140562A (ko) 염증성 질환의 치료를 위한 신규 의약
KR20250150635A (ko) 인자 b 억제제의 사용 방법
WO2025172910A1 (en) Factor b inhibitors for treatment of anca-associated vasculitis
Rista et al. Rituximab Treatment of Membranous Nephropathy after Failure of other Therapies-A Case report
Barratt et al. Atacicept in IgA Nephropathy (IgAN): Continued Protective Titers to Diphtheria and Tetanus and Balanced Infections vs. Placebo with a Focus on COVID-19: SA-PO884
Ingold et al. Successful targeting of the alternative complement cascade with iptacopan for the treatment of IgA nephropathy: a case report
WO2025167710A1 (zh) 三稠环化合物在制备预防和/或治疗炎性疾病药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination